PLBD2: A Potential Drug Target and Biomarker (G196463)

Target Name: PLBD2

NCBI ID: G196463

PLBD2

PLBD2: A Potential Drug Target and Biomarker

Plasma cell lymphoma (PCL) is a type of aggressive B-cell malignancy that originates from the Plasma Cells, a type of white blood cell that produces antibodies. PCL is a rare and aggressive disease that affects both humans and animals and is characterized by the production of a large number of auto-antibodies and the formation of large B-cell clusters in the bone marrow.

PLBD2, which stands for Plic acid-binding protein-2, is a protein that is expressed in various tissues and has been identified as a potential drug target and biomarker in PCL. PLBD2 is a 22-kDa protein that is characterized by the presence of a N-terminal extracellular domain, a transmembrane region, and a C-terminal T-cell antigen (TCA) domain. The TCA domain is a structural protein that is involved in the formation of the T-cell antigen (TCR) and is thought to play a role in the regulation of immune responses.

Studies have shown that PLBD2 is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. For example, studies have shown that PLBD2 is involved in the regulation of T-cell proliferation and differentiation, and that it plays a role in the development of cancer. Additionally, PLBD2 has been shown to be involved in the regulation of inflammation, and that it may be a potential therapeutic target for the treatment of various inflammatory diseases.

As a potential drug target, PLBD2 has the potential to be used to treat a variety of diseases, including PCL, cancer, and autoimmune diseases. For example, studies have shown that inhibiting PLBD2 activity can lead to the regression of PCL tumors in both humans and animals. Additionally, PLBD2 has been shown to be involved in the regulation of cancer cell migration and invasion, and that it may be a potential therapeutic target for the treatment of cancer.

As a potential biomarker, PLBD2 has the potential to be used as a diagnostic tool for various diseases, including PCL, cancer, and autoimmune diseases. For example, studies have shown that PLBD2 levels are elevated in the blood and lymphoid tissues of individuals with PCL, and that they are associated with the development of PCL tumors. Additionally, PLBD2 has been shown to be involved in the regulation of inflammation, and that it may be a potential therapeutic target for the treatment of inflammatory diseases.

In conclusion, PLBD2 is a protein that is expressed in various tissues and has been identified as a potential drug target and biomarker in PCL. PLBD2 is involved in the regulation of various cellular processes and has been shown to be involved in the development and progression of PCL, as well as cancer and autoimmune diseases. As a potential drug target, PLBD2 has the potential to be used to treat a variety of diseases, including PCL, cancer, and autoimmune diseases. As a potential biomarker, PLBD2 has the potential to be used as a diagnostic tool for various diseases, including PCL, cancer, and autoimmune diseases. Further research is needed to fully understand the role of PLBD2 in these diseases and to develop safe and effective therapies that target this protein.

Protein Name: Phospholipase B Domain Containing 2

Functions: Putative phospholipase

The "PLBD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLBD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets